Hai Robotics Joins the United Nations Global Compact
4.9.2023 06:01:00 EEST | Business Wire | Press release
Hai Robotics, a global leading provider of autonomous case-handling robots (ACR) systems, is proud to announce that it has joined the United Nations Global Compact initiative—the world's largest voluntary corporate sustainability initiative.
Hai Robotics joins thousands of organizations across 160 countries that are committed to taking responsible business action to build a more sustainable and inclusive society. Hai Robotics commits to uphold the Ten Principles of the UN Global Compact and support the UN in achieving the Sustainable Development Goals (SDG). Hai Robotics will also share an annual Communication on Progress to showcase its continued engagement.
"At Hai Robotics, we view sustainability as crucial in driving our long-term growth and resilience, and strive to serve as a responsible corporate citizen for our stakeholders," said Richie Chen, Founder and CEO at Hai Robotics. "We are excited to join the UN Global Compact in its mission to accelerate corporate sustainability. As a company continuing to expand globally, we recognize the growing importance of incorporating ESG increasingly into our business strategy. Participating in the UN Global Compact is critical in the improvement of our sustainability efforts during the development of warehouse automation solutions."
Hai Robotics is actively involved in reducing its environmental footprint through sustainable business practices and production methods. Hai Robotics implements action in sustainable sourcing to hold itself accountable across all stages of the supply chain, such as the use of composite wood in packaging. With this new commitment, Hai Robotics will evaluate its existing ESG activities and support for clients to ensure they align with UN's Sustainable Development Goals and create positive impact. For more information on Hai's ESG efforts and commitment, click here to access our annual sustainability report.
As the largest corporate sustainability initiative in the world, the UN Global Compact consists of more than 15,000 companies and 3,800 non-business signatories across over 160 countries, and more than 69 Local Networks. The Sustainable Development Goals consist of 17 global goals aimed to tackle societal issues and improve the quality of life by 2030, covering five key areas of people, planet, prosperity, peace and partnership.
About Hai Robotics
Hai Robotics, a leading global provider of Autonomous Case-handling Robot (ACR) systems, is committed to providing flexible, intelligent, and efficient warehouse automation solutions through robotics technology and AI algorithms. The HaiPick solution, independently developed in 2015, is the world's first ever ACR solution. Hai Robotics is a global enterprise that has more than 1,000 projects worldwide and serves customers from more than 30 countries and regions. We have offices to cover the United States, Europe, Japan, South Korea, Southeast Asia and Australia. We strive to combine global experience with local expertise to provide our customers with tailored, quality solutions. Hai Robotics is also a Participant of the United Nations Global Compact and adhere to its principles-based approach to responsible business. To learn more about Hai Robotics, visit www.hairobotics.com/
About the United Nations Global Compact
As a special initiative of the UN Secretary-General, the United Nations Global Compact is a call to companies everywhere to align their operations and strategies with Ten Principles in the areas of human rights, labour, environment and anti-corruption. Our ambition is to accelerate and scale the global collective impact of business by upholding the Ten Principles and delivering the Sustainable Development Goals through accountable companies and ecosystems that enable change. With more than 15,000 companies and 3,000 non-business signatories based in over 160 countries, and 69 Local Networks, the UN Global Compact is the world’s largest corporate sustainability initiative — one Global Compact uniting business for a better world. For more information, follow @globalcompact on social media and visit our website at unglobalcompact.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230903281684/en/
Contact information
Jennifer Kang
jennifer.kang@hairobotics.com
pr@hairobotics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom